A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
This study was to compare the effect of 156 weeks of treatment with MK-0966 (Rofecoxib)
versus placebo on the recurrence of colorectal adenomas (growths that occur on the inside
(the lining) of the large intestine, also known as the colon) in patients with a history of
colorectal adenomas.